Why Gland Pharma Shares Rose 12% Today and Hit a 52 Week High: Key Reasons Behind the Rally

Gland Pharma shares jumped around 12% on Tuesday, August 11, after the pharmaceutical company reported a strong first quarter performance for FY27. The stock touched an intraday and 52 week high of ₹2,987 on the NSE, compared with the previous close of ₹2,667.30. The shares were trading around ₹2,977 during the session after the early market surge. The June quarter results showed consolidated net profit rising 47% year on year to ₹317 crore, while revenue from core operations increased 19.5% to ₹1,800 crore.

The quarterly performance was supported by strong growth in the US and Europe, along with continued expansion in the company's contract development and manufacturing organisation business. US revenue increased 32% year on year to ₹981 crore, while European revenue rose around 20% to ₹395 crore. EBITDA increased 33% to ₹489 crore and the EBITDA margin expanded to 27.16% from 24.44% a year earlier. Management has also raised its constant currency growth guidance to 15% from the earlier 12% to 13% range, while a new CDMO partnership is estimated to have annualised revenue potential of $90 million to $100 million once all products are commercialised.

Gland Pharma share price and stock performance

Gland Pharma shares rose sharply after the Q1 FY27 results as investors responded to the improvement in revenue, profit and operating margins. The stock reached ₹2,987 during Tuesday's session, marking a new 52 week high according to the supplied market data. The previous close was ₹2,667.30. The stock was trading near ₹2,977 after the early session rally.

Stock metric	Value
Previous close	₹2,667.30
Current price mentioned	₹2,916.00
Intraday and 52 week high	₹2,987
Intraday gain	Around 12%
Gain shown in supplied data	10.15%

Q1 FY27 financial performance

Gland Pharma reported a strong improvement in its June quarter financial performance. Consolidated net profit after tax increased 47% year on year to ₹317 crore from ₹215 crore in the same quarter of the previous year. Revenue from core operations rose 19.5% to ₹1,800 crore from ₹1,506 crore. EBITDA increased 33% to ₹489 crore from ₹368 crore, while the EBITDA margin improved to 27.16% from 24.44%. The numbers show that profit and operating earnings grew faster than revenue during the quarter.

Financial metric	Q1 FY27	Q1 FY26	YoY change
Revenue from core operations	₹1,800 crore	₹1,506 crore	+19.5%
Net profit	₹317 crore	₹215 crore	+47%
EBITDA	₹489 crore	₹368 crore	+33%
EBITDA margin	27.16%	24.44%	Improved

US and Europe revenue growth

The US market was the largest contributor to the revenue increase during the quarter. Revenue from the US segment rose 32% year on year to ₹981 crore. Revenue from Europe increased around 20% to ₹395 crore. The performance in these markets was an important part of the overall revenue growth reported for the June quarter.

Market	Q1 FY27 revenue	Growth
US	₹981 crore	+32% YoY
Europe	₹395 crore	Around +20% YoY

CDMO business and new contract

The company's CDMO business contributed around 50% of total revenue during the quarter and recorded 20% year on year growth. Gland Pharma has also entered into a CDMO partnership with a global pharmaceutical company. The annualised revenue potential from the agreement is estimated at around $90 million to $100 million once all products under the partnership are commercialised.

The actual revenue contribution will depend on product commercialisation and the progress of the partnership. The supplied information does not provide a specific timeline for reaching the full annualised revenue potential.

US product launches and regulatory approvals

Gland Pharma launched four molecules in the US during Q1 FY27, including multi vitamin and leucovorin calcium. The company also filed three ANDAs and received seven approvals during the June quarter. These product launches and regulatory approvals form part of the company's expansion in the US market.

The US remains an important revenue market for the company, with revenue from the region rising 32% year on year during the quarter. Future launches and approvals will therefore remain important factors for revenue growth.

Management raises growth guidance

Following the June quarter performance, management indicated 15% growth guidance in constant currency, compared with its earlier guidance range of 12% to 13%. The change reflects the stronger operating performance reported during Q1 and the company's expectations for the period ahead.

Jefferies analysts said the company had delivered a strong Q1 performance, supported mainly by 32% year on year growth in the US market. The analysts also pointed to progress in the CDMO business, Cenexi reaching breakeven, new contract wins and expansion into complex products as factors supporting the company's outlook.

Are Gland Pharma's growth challenges easing?

The Q1 numbers suggest that several areas of the business have improved, with revenue growth accelerating, EBITDA margins expanding and the US business reporting strong growth. The CDMO business also grew 20% year on year and contributed around half of total revenue. The new partnership adds a potential future revenue stream, although the full contribution depends on product commercialisation.

The increase in management's constant currency growth guidance from 12% to 13% to 15% is another development investors are likely to track. At the same time, future performance will depend on US market growth, product launches, regulatory approvals and the execution of CDMO contracts.

Stock outlook

Gland Pharma's Q1 FY27 results showed higher revenue, faster profit growth and improved EBITDA margins, while the stock moved to a fresh 52 week high after the results. US revenue growth of 32% and the 20% increase in CDMO revenue were among the main operating developments during the quarter. The company has also raised its constant currency growth guidance to 15%. Investors tracking the Gland Pharma share price can monitor US market performance, new product launches, regulatory approvals, CDMO commercialisation and the company's ability to sustain the improved operating margins in the coming quarters.

Why did Gland Pharma shares rise today?

Gland Pharma shares jumped around 12% on August 11 after the company reported strong Q1 FY27 results. The stock touched a 52 week high of ₹2,987, supported by higher revenue, profit and EBITDA, along with improved growth guidance.

What was Gland Pharma's Q1 FY27 net profit?

Gland Pharma reported consolidated net profit of ₹317 crore in Q1 FY27, up 47% from ₹215 crore in the year ago quarter.

What was Gland Pharma's Q1 FY27 revenue?

Revenue from core operations increased 19.5% year on year to ₹1,800 crore in Q1 FY27 from ₹1,506 crore in the corresponding quarter of the previous year.

What was Gland Pharma's EBITDA margin in Q1 FY27?

Gland Pharma's EBITDA margin increased to 27.16% in Q1 FY27 from 24.44% a year earlier.

How much did Gland Pharma's US revenue grow?

Revenue from the US market increased 32% year on year to ₹981 crore during Q1 FY27.

What is Gland Pharma's CDMO revenue growth?

The CDMO business contributed around 50% of total revenue and recorded 20% year on year growth during Q1 FY27.

What is the new Gland Pharma CDMO contract worth?

The new CDMO partnership with a global pharmaceutical company has an estimated annualised revenue potential of $90 million to $100 million once all products are commercialised.

What is Gland Pharma's new growth guidance?

Management has indicated 15% constant currency growth guidance, compared with the earlier guidance range of 12% to 13%.

What products did Gland Pharma launch in the US?

Gland Pharma launched four molecules in the US during Q1 FY27, including multivitamin and leucovorin calcium.

How many ANDAs did Gland Pharma file in Q1 FY27?

The company filed three ANDAs and received seven approvals during the June quarter.

What was Gland Pharma's 52 week high?

Gland Pharma touched an intraday and 52 week high of ₹2,987 on August 11, 2026, according to the supplied market data.

What are investors watching in Gland Pharma?

Investors are likely to track US revenue growth, CDMO contract commercialisation, new product launches, regulatory approvals, Cenexi's performance and operating margins in the coming quarters.